Lawyer profile for UK 2022
Chambers Research is conducted by 200 Research Analysts, across 200 jurisdictions and provides nearly 6,000 rankings tables. Annually we collect hundreds of thousands of responses from clients, the majority via in-depth interview. Learn more about our methodology.
Private Equity: Venture Capital Investment - UK-wide
"Sophie is professional, pleasant and prompt. Her strengths are her knowledge and speed.""She's a good communicator who proposes useful solutions."
This content is provided by Sophie McGrath
Sophie McGrath is a partner in Goodwin’s Technology and Life Sciences group. Ms. McGrath focuses on transactions in the life sciences and technology sectors, acting for companies at all stages of development, as well as investors and management teams. She advises on a wide range of corporate matters, including private and public financings, mergers and acquisitions, public offerings and restructurings. Ms. McGrath has particular expertise advising on cross border transactions including investments into UK or European companies by US or pan-European investors, and exiting these companies by way of sale or IPO.”
Ms. McGrath also has a keen interest in the impact investment sector, acting for both investors and companies that are targeting a “double bottom line,” either through environmental or social impact, and is a member of the British Venture Capital Association’s Impact Investment advisory group, which has a mandate to promote the development of the impact investment sector in the UK.
Prior to joining Goodwin in 2018, Ms. McGrath was a partner at Brown Rudnick.